The takeaway
Nurix Therapeutics Inc shows a pronounced seasonal pattern over 6 years of data — strongest in July (+5.1%) and softest in March (−7.0%).
Right now
In July, the stock has risen 67% of years, averaging +5.1%, about +2.9 pts better than the S&P 500.
The full picture
Nurix Therapeutics Inc's most dependable month has been July, higher in 4 of 6 years; March has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in November (+12.3 pts); it has trailed the market most in March (−8.0 pts).
“vs S&P” is Nurix Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Nurix Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, July has closed higher 60% of the time versus 67% across the last 6 years — the pattern is holding.
Figures are the typical (median) July return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The year leans July's way without overwhelming the rest of it: the stock has closed higher in 4 of 6 Julys, its most dependable month if not a dominant one.
A typical July brings +3.3%, a shade under the +5.1% average. It is also the calendar's calmest month, its returns swinging least from year to year (a 8.4% spread), and even its worst July in 6 years lost only 3.8% — the gentlest downside anywhere on its calendar. Crucially, the gain is the stock's own rather than a rising tide's: July has cleared the S&P 500 by +2.9 points above the index. Some of that is a strong month market-wide, mind — July rises for about 61% of stocks — so the tendency is real if not unique.
A few other months pull their weight: January, April, and August have also closed higher more often than not. At the other end of the calendar, March has been the soft spot — the weakest of 6 months that average a loss (−7.0%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, January, and May. Its roughest month on record was a −37.2% January in 2022 — a reminder of how hard even a seasonal name can fall.
Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (July), its worst (March), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (July, +5.1%) has run well ahead of its worst (March, −7.0%) — the heatmap above shows how steady that gap has been year to year.
July has been the strongest, averaging +5.1% and closing higher in 4 of 6 years since 2020.
It's the weakest, averaging −7.0% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade